68 results
Page 3 of 4
8-K
7to7 q1q6
18 Dec 19
Entry into a Material Definitive Agreement
7:16am
8-K
EX-99.1
qrveu
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.2
4g2xoqw9 v9
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
8nu8rbg3fcpk xs9
8 Apr 19
Prospectus supplement for primary offering
12:00am
424B5
g0rrjdf13zfqmh0l6or
8 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
tfdov0kuulee j4eq
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
uejo vs6aijq
4 Apr 19
Prospectus supplement for primary offering
4:15pm
424B5
c2ypy1sczt
4 Apr 19
Prospectus supplement for primary offering
4:13pm
8-K
EX-99.2
latsp9pq45 br37w7wg6
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.1
7g0wydfdti6144lwtugw
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.1
cxy9c4oozyrv
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.2
jsnajdx
15 Nov 18
Regulation FD Disclosure
4:03pm
8-K
g93hafca3v kgsv8
26 Sep 18
Other Events
8:31am